BackgroundCheck.run
Search For

Hui Zhang4232 Pine, Philadelphia, PA 19104

Known as:
Hui Z Hang
Related to:
Xiaoxi X Zhang 52 Liangyue X Zhang 48 Mei Ya Zhang

Hui Zhang Phones & Addresses

4232 Pine, Philadelphia, PA 19104    215-3863547   

Phila, PA   

Waterville, ME   

Alamogordo, NM   

Worcester, MA   

Brooklyn, NY   

Get Report
Control this profile

Mentions for Hui Zhang

Career records & work history

Lawyers & Attorneys

Hui Zhang Photo 1

Hui Zhang - Lawyer

Specialties:
General IP Advice, Trademark Registration and Advice, Patent, IP Enforcement and Anti-Piracy, Copyright
ISLN:
915338281
Admitted:
2000
University:
Chongqing, P.R.C., 1991
Law School:
Renmin University of China, Beijing, P.R.C., LL.M., 2001
Hui Zhang Photo 2

Hui Zhang - Lawyer

Office:
Rabin & Berdo, P.C.
ISLN:
1000472958
Admitted:
Virginia
Hui Zhang Photo 3

Hui Zhang - Lawyer

Address:
O'Melveny & Myers LLP
106-5634200 (Office)
Licenses:
New York - Currently registered 2005
Education:
Franklin Pierce
Hui Zhang Photo 4

Hui Zhang - Lawyer

ISLN:
1000709650
Admitted:
2013

Medicine Doctors

Hui Z. Zhang

Specialties:
Genetics, Medical
Work:
Yale University School Genetics Consultation Services
3333 Cedar St, New Haven, CT 06510
203-7852660 (phone) 203-7853404 (fax)
Education:
Medical School
Shanghai Med Univ, Shanghai First Med Univ, Shanghai, China
Graduated: 1988
Conditions:
Cleft Palate and Cleft Lip, Hearing Loss, Undescended and Retractile Testicle
Languages:
English, Spanish
Description:
Dr. Zhang graduated from the Shanghai Med Univ, Shanghai First Med Univ, Shanghai, China in 1988. She works in New Haven, CT and specializes in Genetics, Medical. Dr. Zhang is affiliated with Yale New Haven Hospital.

Hui Zhang

Specialties:
Hematology/Oncology, Internal Medicine
Work:
HSHS Medical GroupHSHS Medical Group Cancer Institute
301 N 8 St, Springfield, IL 62701
217-5255640 (phone) 217-7576754 (fax)
Site
HSHS Medical GroupHSHS Medical Group Cancer Institute
1215 Franciscan Dr FL 2, Litchfield, IL 62056
217-5255640 (phone) 217-3248740 (fax)
Site
Languages:
English
Description:
Dr. Zhang works in Litchfield, IL and 1 other location and specializes in Hematology/Oncology and Internal Medicine. Dr. Zhang is affiliated with Saint Francis Hospital, Saint Johns Hospital and Saint Marys Hospital.

License Records

Hui Lan Zhang

Licenses:
License #: 6301014375 - Active
Category: Psychology
Issued Date: Dec 19, 2014
Expiration Date: Aug 31, 2017
Type: Psychologist

Hui Lan Zhang

Licenses:
License #: 6301014375 - Expired
Category: Psychology
Issued Date: Dec 22, 2009
Expiration Date: Aug 31, 2015
Type: Psychologist - Doctoral Educ Ltd

Hui Zhang

Licenses:
License #: 27433 - Active
Issued Date: May 22, 2009
Renew Date: Dec 1, 2015
Expiration Date: Nov 30, 2017
Type: Certified Public Accountant

Hui Zhang

Licenses:
License #: 0225189150
Category: Real Estate Individual

Hui Y Zhang

Address:
Philadelphia, PA 19148
Licenses:
License #: 010014 - Expired
Category: Cosmetology
Type: Nail Technician Temp Auth to Practice

Hui Y Zhang

Address:
Philadelphia, PA 19148
Licenses:
License #: CL186637 - Active
Category: Cosmetology
Type: Nail Technician

Hui Ying Zhang

Address:
Philadelphia, PA 19148
Licenses:
License #: CQ116063 - Active
Category: Cosmetology
Type: Esthetician

Hui Z Zhang

Address:
Philadelphia, PA 19152
Licenses:
License #: 005493 - Active
Category: Cosmetology
Type: Esthetician Temp Authority to Practice

Publications & IP owners

Us Patents

Multimerization Of Hiv-1 Vif Protein As A Therapeutic Target

US Patent:
6653443, Nov 25, 2003
Filed:
Apr 8, 2002
Appl. No.:
10/118575
Inventors:
Hui Zhang - Philadelphia PA
Roger J. Pomerantz - Chalfont PA
Bin Yang - Bala Cynwyd PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
A61K 3804
US Classification:
530327, 530324, 530325, 530326, 530826
Abstract:
One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif, by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.

Multimerization Of Hiv-1 Vif Protein As A Therapeutic Target

US Patent:
7226741, Jun 5, 2007
Filed:
Oct 17, 2003
Appl. No.:
10/688100
Inventors:
Hui Zhang - Philadelphia PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435 911, 435 9133
Abstract:
One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known, the vif gene is essential for the pathogenic replication of lentiviruses in vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by interfering with the replicative or other essential functions of HIV-1 viral protein Vif by interactively blocking the multimerization domain of Vif, thereby preventing multimerization of Vif protein, which is important for Vif function in the lentivirus life cycle. In preferred embodiments, the compound or compounds that interactively block the multimerization domain of Vif are Vif antagonists. Pharmaceutical compositions comprising these compounds are also disclosed.

Multimerization Of Hiv-1 Vif Protein As A Therapeutic Target

US Patent:
7498138, Mar 3, 2009
Filed:
Jun 4, 2007
Appl. No.:
11/809953
Inventors:
Hui Zhang - Philadelphia PA, US
Roger J. Pomerantz - Chalfont PA, US
Bin Yang - Bala Cynwyd PA, US
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12Q 1/68
US Classification:
435 6, 435 911
Abstract:
The HIV-1 protein Vif comprises a multimerization domain that allows Vif-Vif interaction and Vif multimerization, which is important for Vif function in the HIV-1 life-cycle. A method for screening for an antagonist of Vif comprises contacting the multimerization domain of Vif with a test compound that specifically binds the multimerization domain. Antagonists identified by the screening assay inhibit Vif multimerization. The antagonists inhibit essential functions of Vif and accordingly are useful as inhibitors of HIV-1 replication.

Peptide And Treatment For Hiv-1 Infection

US Patent:
8334255, Dec 18, 2012
Filed:
Dec 4, 2007
Appl. No.:
12/448058
Inventors:
Hui Zhang - Voorhees NJ, US
Harold C. Smith - Rochester NY, US
Assignee:
Thomas Jefferson University - Philadelphia PA
OyaGen Inc. - Rochester NY
International Classification:
A61K 38/16
A61K 38/08
C07K 14/00
C07K 7/06
C07K 7/08
US Classification:
514 38, 514 11, 514 37, 530324, 530325, 530326, 530327, 530328
Abstract:
A compound of the formula X-M-SEQ ID NO:1, or a derivative thereof, is provided, wherein X-M- represents an optional group comprising a protein transduction domain conjugated to the N-terminus of the amino acid sequence SEQ ID NO:1. Pharmaceutical compositions comprising and therapeutic methods using the compound are also provided.

Method For Increasing Transduction Efficiency Of Recombinant Retroviral Vectors

US Patent:
5763242, Jun 9, 1998
Filed:
Feb 8, 1995
Appl. No.:
8/385446
Inventors:
Hui Zhang - Philadelphia PA
Roger J. Pomerantz - Chalfont PA
Assignee:
Thomas Jefferson University - Philadelphia PA
International Classification:
C12N 1500
C12N 1586
C12N 510
US Classification:
4351723
Abstract:
A method for improving the transduction efficiency of retroviral vectors into a host cell wherein the retroviral vectors are incubated with deoxyribonucleoside triphosphates prior to transduction into the host cell is provided.

Log-Based Computer System Failure Signature Generation

US Patent:
2019007, Mar 14, 2019
Filed:
Jul 12, 2018
Appl. No.:
16/033278
Inventors:
- Princeton NJ, US
Jianwu Xu - Lawrenceville NJ, US
Hui Zhang - Princeton Junction NJ, US
International Classification:
G06F 11/07
Abstract:
Systems and methods for automatically generating failure signatures in a computer system for performing computer system fault diagnosis are provided. The method includes receiving log data, converting each log in the log data into a collection of log pattern sequences including one or more log pattern sequences corresponding to one or more respective failure categories associated with the computer system, generating a collection of seed patterns by computing a global set of patterns from the collection of log pattern sequences, and extracting the collection of seed patterns from the global set of patterns, generating a log pattern grammar representation for each of the one or more log pattern sequences, generating a failure signature for each of the one or more failure categories based on the log pattern grammar representation and the collection of seed patterns, and employing the failure signatures to perform computer system fault diagnosis on new log data.

Anomaly Fusion On Temporal Casualty Graphs

US Patent:
2017023, Aug 17, 2017
Filed:
Nov 15, 2016
Appl. No.:
15/351449
Inventors:
- Princeton NJ, US
Jianwu Xu - Lawrenceville NJ, US
Hui Zhang - Princeton Junction NJ, US
Guofei Jiang - Princeton NJ, US
International Classification:
G06F 11/07
G06N 7/00
G06N 5/04
Abstract:
An exemplary method for detecting one or more anomalies in a system includes building a temporal causality graph describing functional relationship among local components in normal period; applying the causality graph as a propagation template to predict a system status by iteratively applying current system event signatures; and detecting the one or more anomalies of the system by examining related patterns on the template causality graph that specifies normal system behaviors. The system can aligning event patterns on the causality graph to determine an anomaly score.

Fast Pattern Discovery For Log Analytics

US Patent:
2017023, Aug 17, 2017
Filed:
Nov 15, 2016
Appl. No.:
15/351452
Inventors:
- Princeton NJ, US
Jianwu Xu - Lawrenceville NJ, US
Hui Zhang - Princeton Junction NJ, US
Guofei Jiang - Princeton NJ, US
International Classification:
G06K 9/46
G06F 17/30
Abstract:
Systems and methods are disclosed for parsing logs from arbitrary or unknown systems or applications by capturing heterogeneous logs from the arbitrary or unknown systems or applications; generating one pattern for every unique log message; building a pattern hierarchy tree by grouping patterns based on similarity metrics, and for every group it generates one pattern by combing all constituting patterns of that group; and selecting a set of patterns from the pattern hierarchy tree.

Possible Relatives

David Zhang  Dawei Zhang  Dazhi Zhang  De K Zhang  Da Q Zhang  Dachuan Zhang  Daijun Zhang  Hui S Jun  Hui T Lee  Hui Li 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.